Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells

Bian,Yuan; Li,Qiu; Li,Qiaolian; Pan,Ruigen

doi:10.3892/mmr.2020.11285

Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells

Authors:
- Yuan Bian
- Qiu Li
- Qiaolian Li
- Ruigen Pan
View Affiliations

Affiliations: Department of Respiratory Medicine, Zhuji Affiliated Hospital of Shaoxing University, Zhuji, Zhejiang 311800, P.R. China, Department of Radiology, Zhuji Affiliated Hospital of Shaoxing University, Zhuji, Zhejiang 311800, P.R. China
Published online on: June 26, 2020 https://doi.org/10.3892/mmr.2020.11285
Pages: 1767-1774
Copyright: © Bian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transcription factor II B (TFIIB)‑related factor 2 (BRF2) is involved in the development of cancer, but its role in lung cancer is underreported. The present study aimed to explore the role of BRF2 in the regulation of lung cancer cells. Immunofluorescence staining and immunohistochemistry were performed to detect BRF2 protein expression in human lung cancer cells and tissues. Following cell transfection with small interfering RNA for silencing BRF2, the cell proliferation was examined by Cell Counting Kit‑8 and MTT assays. Cell apoptosis, migration and invasion were determined by flow cytometry, wound‑healing and Transwell assay. The expression levels of Akt, phosphorylated (p)‑Akt, Bax, E‑cadherin, Bcl‑2, N‑cadherin, Snail and epidermal growth factor receptor (EGFR) in human lung cancer A549 cells were detected by western blotting. The results demonstrated that BRF2 expression was increased in human lung cancer cells and tissues, and that silencing of BRF2 promoted cell apoptosis but inhibited cell proliferation and migration. The protein expression levels of Akt, E‑cadherin, p‑Akt, Bcl‑2, N‑cadherin, Snail and EGFR in A549 cells were inhibited by silencing of BRF2, while expression levels of Bax and E‑cadherin were increased by silencing BRF2. In conclusion, BRF2 demonstrates high expression in lung cancer and silencing of BRF2 inhibits the growth and metastasis of lung cancer cells. The current findings provide a novel approach for the treatment of lung cancer.

View Figures

View References

1	Liu H, Han L, Liu Z and Gao N: Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway. J Cell Physiol. 234:13843–13850. 2019. View Article : Google Scholar : PubMed/NCBI
2	Wang L, Qu J, Zhou L, Liao F and Wang J: MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line. Cancer Res Treat. 50:936–949. 2018. View Article : Google Scholar : PubMed/NCBI
3	Lu J and Han B: Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. Technol Cancer Res Treat. 17:15330338188018092018. View Article : Google Scholar : PubMed/NCBI
4	Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: Diagnosis and management. Am Fam Physician. 75:56–63. 2007.PubMed/NCBI
5	Tian Y, Wang C and Lu M: BRF2 as a promising indicator for radical lymph-node dissection surgery in patients with cN0 squamous cell carcinoma of the middle thoracic esophagus. Surg Today. 49:158–169. 2019. View Article : Google Scholar : PubMed/NCBI
6	Verma N, Hurlburt AM, Wolfe A, Kim MK, Kang YS, Kang JJ and Stumph WE: Bdp1 interacts with SNAPc bound to a U6, but not U1, snRNA gene promoter element to establish a stable protein-DNA complex. FEBS Lett. 592:2489–2498. 2018. View Article : Google Scholar : PubMed/NCBI
7	McQueen C, Hughes GL and Pownall ME: Skeletal muscle differentiation drives a dramatic downregulation of RNA polymerase III activity and differential expression of Polr3g isoforms. Dev Biol. 454:74–84. 2019. View Article : Google Scholar : PubMed/NCBI
8	Geiduschek EP and Kassavetis GA: The RNA polymerase III transcription apparatus. J Mol Biol. 310:1–26. 2001. View Article : Google Scholar : PubMed/NCBI
9	Saxena A, Ma B, Schramm L and Hernandez N: Structure-function analysis of the human TFIIB-related factor II protein reveals an essential role for the C-terminal domain in RNA polymerase III transcription. Mol Cell Biol. 25:9406–9418. 2005. View Article : Google Scholar : PubMed/NCBI
10	Song W, Filonov GS, Kim H, Hirsch M, Li X, Moon JD and Jaffrey SR: Imaging RNA polymerase III transcription using a photostable RNA-fluorophore complex. Nat Chem Biol. 13:1187–1194. 2017. View Article : Google Scholar : PubMed/NCBI
11	Scott PH, Cairns CA, Sutcliffe JE, Alzuherri HM, McLees A, Winter AG and White RJ: Regulation of RNA polymerase III transcription during cell cycle entry. J Biol Chem. 276:1005–1014. 2001. View Article : Google Scholar : PubMed/NCBI
12	Lei J, Chen S and Zhong S: Abnormal expression of TFIIIB subunits and RNA Pol III genes is associated with hepatocellular carcinoma. Liver Res. 1:112–120. 2017. View Article : Google Scholar : PubMed/NCBI
13	White RJ: RNA polymerase III transcription - a battleground for tumour suppressors and oncogenes. Eur J Cancer. 40:21–27. 2004. View Article : Google Scholar : PubMed/NCBI
14	Cabarcas S, Jacob J, Veras I and Schramm L: Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells. BMC Mol Biol. 9:742008. View Article : Google Scholar : PubMed/NCBI
15	Johnson SA, Dubeau L, Kawalek M, Dervan A, Schönthal AH, Dang CV and Johnson DL: Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. Mol Cell Biol. 23:3043–3051. 2003. View Article : Google Scholar : PubMed/NCBI
16	Srihari S, Kalimutho M, Lal S, Singla J, Patel D, Simpson PT, Khanna KK and Ragan MA: Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. Mol Biosyst. 12:963–972. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, et al: Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol. 16:1072015. View Article : Google Scholar : PubMed/NCBI
18	Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Zhu CQ, et al: Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med. 7:e10003152010. View Article : Google Scholar : PubMed/NCBI
19	Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Luís A, McCarthy N, Montibeller L, More S, et al: Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. FEBS J. 286:241–278. 2019. View Article : Google Scholar : PubMed/NCBI
20	Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, Ozdag H, Vias M, Kranjac T, Subkhankulova T, Paish C, et al: A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene. 24:5235–5245. 2005. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Guo Q, Li H, Liu J, Xu L, Yang L, Sun Z and Zhou B: Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma. J Asthma. 54:125–133. 2017. View Article : Google Scholar : PubMed/NCBI
23	Jin J, Zhao L, Zou W, Shen W, Zhang H and He Q: Activation of Cyclooxygenase-2 by ATF4 During Endoplasmic Reticulum Stress Regulates Kidney Podocyte Autophagy Induced by Lupus Nephritis. Cell Physiol Biochem. 48:753–764. 2018. View Article : Google Scholar : PubMed/NCBI
24	Thawani R, McLane M, Beig N, Ghose S, Prasanna P, Velcheti V and Madabhushi A: Radiomics and radiogenomics in lung cancer: A review for the clinician. Lung Cancer. 115:34–41. 2018. View Article : Google Scholar : PubMed/NCBI
25	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
26	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
27	Hashemi ZS, Khalili S, Forouzandeh Moghadam M and Sadroddiny E: Lung cancer and miRNAs: A possible remedy for anti-metastatic, therapeutic and diagnostic applications. Expert Rev Respir Med. 11:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
28	Melchor L, Garcia MJ, Honrado E, Pole JC, Alvarez S, Edwards PA, Caldas C, Brenton JD and Benítez J: Genomic analysis of the 8p11-12 amplicon in familial breast cancer. Int J Cancer. 120:714–717. 2007. View Article : Google Scholar : PubMed/NCBI
29	Cabarcas S and Schramm L: RNA polymerase III transcription in cancer: The BRF2 connection. Mol Cancer. 10:472011. View Article : Google Scholar : PubMed/NCBI
30	Rosenwald IB: The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene. 23:3230–3247. 2004. View Article : Google Scholar : PubMed/NCBI
31	Yang WB, Zhang WP, Shi JL and Wang JW: miR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway. Eur Rev Med Pharmacol Sci. 22:3408–3414. 2018.PubMed/NCBI
32	Khodapasand E, Jafarzadeh N, Farrokhi F, Kamalidehghan B and Houshmand M: Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? Iran Biomed J. 19:69–75. 2015.PubMed/NCBI
33	Sigismund S, Avanzato D and Lanzetti L: Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018. View Article : Google Scholar : PubMed/NCBI
34	Farmakovskaya M, Khromova N, Rybko V, Dugina V, Kopnin B and Kopnin P: E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth. Cell Cycle. 15:1084–1092. 2016. View Article : Google Scholar : PubMed/NCBI
35	Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S and Paz-Ares L: The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Sci Rep. 8:23942018. View Article : Google Scholar : PubMed/NCBI
36	Zhang K, Li XY, Wang ZM, Han ZF and Zhao YH: miR-22 inhibits lung cancer cell EMT and invasion through targeting Snail. Eur Rev Med Pharmacol Sci. 21:3598–3604. 2017.PubMed/NCBI
37	Tian Y, Lu M, Yue W, Li L, Li S, Gao C, Si L, Qi L, Hu W and Tian H: TFIIB-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition. BioMed Res Int. 2014:5307862014. View Article : Google Scholar : PubMed/NCBI
38	Gouge J, Satia K, Guthertz N, Widya M, Thompson AJ, Cousin P, Dergai O, Hernandez N and Vannini A: Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2. Cell. 163:1375–1387. 2015. View Article : Google Scholar : PubMed/NCBI